Xeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results

Xeris Biopharma (NASDAQ:XERS) released its quarterly earnings results on Thursday. The company reported $0.01 EPS for the quarter, FiscalAI reports. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Q1 net product revenue rose 43% to $82.5M (total revenue $83.1M) and management raised FY revenue guidance to $380M–$390M, lifting the low end of prior guidance.
• RECORLEV nearly doubled to $49.8M on record referrals and new patient starts, and the company completed its commercial expansion (?80 reps, targets increased to ~12,000), with incremental impact expected in H2.
• Gvoke was flat at $20.8M and underperformed internal expectations due to Medicare policy/plan resets that raised out?of?pocket costs and reduced prescription fills; management expects a recovery later in the year.
• The pipeline candidate XP?8121 is on track to start Phase III later this year, leveraging the company’s XeriSol and device capabilities, with R&D spend planned to increase to support the program.
• Profitability metrics improved—gross margin 87% (+2%), adjusted EBITDA $15.1M, and net income $2.2M—with management reiterating a commitment to positive adjusted EBITDA for 2026 despite higher SG&A and R&D investments.

Xeris Biopharma Price Performance

Xeris Biopharma stock traded up $0.26 during trading hours on Thursday, reaching $6.63. 5,563,284 shares of the stock were exchanged, compared to its average volume of 1,314,657. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10. Xeris Biopharma has a twelve month low of $4.30 and a twelve month high of $10.08. The company has a market cap of $1.14 billion, a P/E ratio of -662.34 and a beta of 0.85. The stock has a 50 day moving average of $5.92 and a two-hundred day moving average of $6.96.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $6.25, for a total value of $104,168.75. Following the transaction, the insider directly owned 1,226,507 shares of the company’s stock, valued at $7,665,668.75. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James Aloysius Brady sold 10,834 shares of the business’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $5.54, for a total transaction of $60,020.36. Following the transaction, the director owned 89,166 shares of the company’s stock, valued at approximately $493,979.64. This represents a 10.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 60,835 shares of company stock valued at $367,860 over the last 90 days. Corporate insiders own 6.47% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of XERS. Corient Private Wealth LLC bought a new stake in shares of Xeris Biopharma during the 4th quarter worth $84,000. VARCOV Co. bought a new position in Xeris Biopharma in the fourth quarter valued at about $243,000. Virtus Investment Advisers LLC raised its stake in Xeris Biopharma by 44.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 37,102 shares of the company’s stock worth $291,000 after acquiring an additional 11,358 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Xeris Biopharma by 63.7% in the fourth quarter. Millennium Management LLC now owns 859,051 shares of the company’s stock worth $6,744,000 after acquiring an additional 334,302 shares during the last quarter. Finally, Man Group plc bought a new position in shares of Xeris Biopharma in the fourth quarter worth about $375,000. Institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

XERS has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a report on Monday, March 2nd. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.